98 related articles for article (PubMed ID: 10847956)
1. Quantitative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass.
Stammers AH; Christensen KA; Lynch J; Zavadil DP; Deptula JJ; Sydzyik RT
J Extra Corpor Technol; 1999 Sep; 31(3):135-41. PubMed ID: 10847956
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
[TBL] [Abstract][Full Text] [Related]
3. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
4. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
[TBL] [Abstract][Full Text] [Related]
5. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
[TBL] [Abstract][Full Text] [Related]
6. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass.
Lundblad R; Moen O; Fosse E
Ann Thorac Surg; 1997 May; 63(5):1361-7. PubMed ID: 9146328
[TBL] [Abstract][Full Text] [Related]
8. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
[TBL] [Abstract][Full Text] [Related]
9. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
[TBL] [Abstract][Full Text] [Related]
10. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
[TBL] [Abstract][Full Text] [Related]
11. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
[TBL] [Abstract][Full Text] [Related]
12. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
Ovrum E; Am Holen E; Tangen G; Ringdal MA
Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
[TBL] [Abstract][Full Text] [Related]
13. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome.
Svenmarker S; Häggmark S; Jansson E; Lindholm R; Appelblad M; Sandström E; Aberg T
Scand Cardiovasc J; 2002 Aug; 36(4):241-6. PubMed ID: 12201973
[TBL] [Abstract][Full Text] [Related]
14. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
[TBL] [Abstract][Full Text] [Related]
15. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass.
Ask A; Holt D; Smith L
J Extra Corpor Technol; 2006 Mar; 38(1):27-32. PubMed ID: 16637520
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
17. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
[TBL] [Abstract][Full Text] [Related]
18. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
Videm V; Mollnes TE; Bergh K; Fosse E; Mohr B; Hagve TA; Aasen AO; Svennevig JL
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):803-9. PubMed ID: 10096977
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of heparin-coated circuits with full heparin dose strategy.
Sinci V; Kalaycioglu S; Gunaydin S; Imren Y; Gokgoz L; Soncul H; Ersoz A
Ann Thorac Cardiovasc Surg; 1999 Jun; 5(3):156-63. PubMed ID: 10413761
[TBL] [Abstract][Full Text] [Related]
20. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
